Astria Therapeutics, Inc. (ATXS)

Market Cap	427.21M
Revenue (ttm)	n/a
Net Income (ttm)	-100.04M
Shares Out	56.43M
EPS (ttm)	-1.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	219,788
Open	7.55
Previous Close	7.50
Day's Range	7.50 - 7.74
52-Week Range	7.16 - 16.90
Beta	0.70
Analysts	Strong Buy
Price Target	25.60 (+238.18%)
Earnings Date	Mar 3, 2025

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder ass...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS
• Website: https://www.astriatx.com

Analyst Forecast

According to 5 analysts, the average rating for ATXS stock is "Strong Buy." The 12-month stock price forecast is $25.6, which is an increase of 238.18% from the latest price.

Price Target

$25.6

(238.18% upside)

Analyst Consensus: Strong Buy